New Hope, PA, United States of America

Kazimierz Chrzan

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Sanofi-Aventis. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazimierz Chrzan. Retrieved from https://idiyas.com/inventor/kazimierz-chrzan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazimierz Chrzan: Innovator in Pharmaceutical Formulations

Introduction

Kazimierz Chrzan is a notable inventor based in New Hope, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His work has led to advancements that benefit patients and healthcare providers alike.

Latest Patents

Kazimierz Chrzan holds a patent for a fexofenadine suspension formulation. This invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I. This formulation is crucial for improving the delivery and effectiveness of the medication.

Career Highlights

Chrzan is associated with Sanofi-Aventis, a leading global biopharmaceutical company. His role at the company has allowed him to focus on innovative solutions in drug formulation and development. His expertise has contributed to the advancement of pharmaceutical sciences.

Collaborations

Kazimierz has collaborated with notable colleagues, including Rajiv Haribhakti and Matthew Mermey. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kazimierz Chrzan's contributions to pharmaceutical formulations exemplify the impact of innovation in healthcare. His work continues to influence the development of effective medications for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…